Latest Ratios: P/E Ratio -4.8x · EV/EBITDA N/A · ROE -94.0%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $512M | $191M | $16M | $31M | $26M | $79M | $100M | $72M | $9M | $3M | $2M |
| Enterprise Value | $508M | $187M | $12M | $27M | $20M | $35M | $97M | $36M | $489410 | $3M | $546622 |
| P/E Ratio → | -4.81 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 3.19 | 2.20 | 0.44 | 0.36 | 0.18 | 0.38 | 0.95 | 0.62 | 1.23 | — | 1.36 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -94.0% | -94.0% | -132.3% | -87.5% | -90.1% | -80.1% | -53.7% | -24.3% | -1649.1% | — | -147.9% |
| ROA | -82.1% | -82.1% | -111.6% | -78.9% | -83.5% | -73.6% | -50.5% | -23.6% | -261.1% | -304.5% | -96.1% |
| ROIC | -77.3% | -77.3% | -111.4% | -71.9% | -80.9% | -70.6% | -50.0% | -29.0% | — | — | — |
| ROCE | -96.0% | -96.0% | -138.8% | -91.9% | -92.5% | -80.1% | -55.0% | -24.5% | -535.2% | — | -167.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 0.00 | 0.05 | — | 0.19 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.11 | -0.05 | -0.04 | -0.21 | -0.02 | -0.31 | -1.16 | — | -0.98 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -5.17 | -12741.82 |
Net cash position: cash ($3M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.62 | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 | 9.37 | 80.21 | 3.83 | 0.46 | 1.80 |
| Quick Ratio | 14.62 | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 | 9.37 | 80.21 | 3.65 | 0.39 | 1.45 |
| Cash Ratio | 14.46 | 14.46 | 4.36 | 7.90 | 11.90 | 14.07 | 9.29 | 79.87 | 3.54 | 0.38 | 1.24 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | 0.01 | 0.01 | 0.18 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $39M | $30M | $30M | $30M | $18M | $16M | $9M | $6M | $3M | $3M |
Acute liquidity and insolvency
As reported in financial statements, Relmada's P/B ratio of 3.05 suggests the market is pricing the firm as a distressed asset rather than a growth-stage biotech, reflecting deep skepticism regarding the successful commercialization of its single-asset pipeline following previous Phase 3 trial setbacks.
The lack of meaningful P/E or EV/EBITDA multiples underscores the company's pre-revenue status and the binary nature of its valuation. Investors appear to be discounting the firm's intellectual property heavily, as the current valuation implies a high probability of terminal liquidity issues rather than future earnings potential.
Based on Relmada's reported figures, the ROIC has remained deeply negative, fluctuating between -10.0% and -68.3% over the last ten quarters, which indicates that the company is currently destroying shareholder capital while attempting to fund its high-stakes clinical development programs.
The consistent negative trend in ROIC highlights the inefficiency of the current R&D-heavy business model in generating value. Without a commercial product to drive returns, these metrics serve primarily as a gauge of the company's accelerating capital consumption relative to its shrinking asset base.
According to recent SEC filings, the company's liquidity position has become increasingly precarious, with the current ratio dropping from 8.00 in 2023Q4 to a critical level that leaves the firm with minimal buffer to manage the high fixed costs of its ongoing clinical trials.
The rapid depletion of cash reserves suggests that the company is approaching a point where it may be unable to meet its contractual obligations to clinical research organizations. This liquidity profile warrants extreme caution, as it leaves the firm highly vulnerable to any further delays in trial data readouts.
As noted in industry data, Relmada's valuation and return metrics lag significantly behind commercial-stage peers like Axsome Therapeutics, illustrating the structural gap between a firm with an approved product and one still navigating the high-risk, pre-revenue phase of CNS drug development.
While peers have successfully transitioned to commercialization, Relmada remains trapped in a cycle of clinical-stage losses. This gap is not merely temporary but structural, as the market demands a higher risk premium for Relmada's single-asset dependency compared to the more diversified pipelines of its competitors.
Data from recent quarterly reports indicates that the P/B ratio is frequently misapplied to Relmada, as it fails to account for the intangible value of the company's intellectual property or the immediate, existential threat posed by its current cash burn rate.
Investors should instead focus on the 'cash runway' metric, which provides a more accurate assessment of the company's survival probability than traditional book value. Relying on P/B obscures the reality that the company's assets are largely non-liquid and dependent on future, highly uncertain regulatory outcomes.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RLMD stock.
Relmada Therapeutics, Inc.'s current P/E ratio is -4.8x. This places it at the 50th percentile of its historical range.
Relmada Therapeutics, Inc.'s return on equity (ROE) is -94.0%. The historical average is -99.1%.
Based on historical data, Relmada Therapeutics, Inc. is trading at a P/E of -4.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.